Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Glaukos Corporation    GKOS

GLAUKOS CORPORATION

(GKOS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
77.19(c) 77.99(c) 84.18(c) 86.71(c) 86.34(c) Last
197 566 233 788 737 100 1 116 809 295 657 Volume
-1.33% +1.04% +7.94% +3.01% -0.43% Change
More quotes
Financials (USD)
Sales 2020 219 M - -
Net income 2020 -124 M - -
Net cash position 2020 201 M - -
P/E ratio 2020 -31,4x
Yield 2020 -
Sales 2021 290 M - -
Net income 2021 -57,6 M - -
Net cash position 2021 216 M - -
P/E ratio 2021 -71,5x
Yield 2021 -
Capitalization 3 880 M 3 880 M -
EV / Sales 2020 16,8x
EV / Sales 2021 12,6x
Nbr of Employees 600
Free-Float 96,8%
More Financials
Company
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the... 
More about the company
Notations Surperformance© of Glaukos Corporation
Trading Rating : Investor Rating :
More Ratings
All news about GLAUKOS CORPORATION
05:12aGLAUKOS : Looking Ahead To Avoid Spoliation Sanctions
AQ
01/13GLAUKOS : Study Shows iStent Infinite Device Substantially Reduces Intraocular P..
MT
01/13GLAUKOS : Announces Preliminary Q4 Sales Above Street Expectation
MT
01/13GLAUKOS CORP : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
01/13GLAUKOS : Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net..
BU
01/13GLAUKOS : rsquo; iDose® TR Demonstrates Sustained IOP Reduction and Favorable Sa..
BU
01/13GLAUKOS : U.S. IDE Trial Results for Glaukos' iStent infinite™ Show Substa..
BU
2020GLAUKOS : Announces Participation in J.P. Morgan Healthcare Conference
BU
2020INSIDER TRENDS : Glaukos Insider Receives Stock Award, Trend of Buys Extended
MT
2020INSIDER TRENDS : Glaukos Insider Receives Stock Award, Buy Trend Intact
MT
2020INSIDER TRENDS : Glaukos Insider Granted Stock Award, Extends Buy Trend
MT
2020GLAUKOS : Citigroup Upgrades Glaukos to Neutral From Sell, Adjusts Price Target ..
MT
2020Oppenheimer Starts Glaukos at Perform With $73 Price Target
MT
2020GLAUKOS CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, ..
AQ
2020Wells Fargo Upgrades Glaukos to Equal-Weight From Underweight; Price Target i..
MT
More news
News in other languages on GLAUKOS CORPORATION
2017Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on GLAUKOS CORPORATION
More recommendations
Chart GLAUKOS CORPORATION
Duration : Period :
Glaukos Corporation Technical Analysis Chart | GKOS | US3773221029 | MarketScreener
Technical analysis trends GLAUKOS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 63,80 $
Last Close Price 86,34 $
Spread / Highest target -7,34%
Spread / Average Target -26,1%
Spread / Lowest Target -44,4%
EPS Revisions
Managers and Directors
NameTitle
Thomas William Burns President, Chief Executive Officer & Director
William J. Link Chairman
Chris M. Calcaterra Chief Operating Officer
Joseph E. Gilliam CFO, CAO & Senior VP-Corporate Development
L. Jay Katz Chief Medical Officer
Sector and Competitors